Fertility benefits stopped being a differentiator a while ago. They are now an expectation, and the shift happened faster than most benefits teams planned for. 42% of employers now offer fertility benefits, up from 30% in 2020, according to SHRM. Egg freezing coverage has grown from 2% of employers a decade ago to 18% today, per the same IFEBP data cited by Forbes. The category has moved from niche to standard, and the market has responded with a wave of vendors, each claiming to be the comprehensive solution.
That growth has created a real problem for both sides of the table. Employers are choosing between a crowded field of platforms with overlapping claims and little standardization. Vendors are competing in a market where differentiation is getting harder to communicate and easier to fake.
What Employers Should Be Evaluating
The vendors worth serious consideration solve for more than IVF reimbursement. Family building today includes egg freezing, adoption, surrogacy, and donor-assisted paths, and the strongest programs are built for single parents, LGBTQ+ employees, and the full range of routes to parenthood. A narrow benefit design signals a vendor that built for yesterday’s workforce.
Clinical quality deserves more scrutiny than it typically gets. Employers should ask vendors for outcome data alongside network size. A large provider list means little if success rates and patient experience within that network are inconsistent. The strongest vendors can show utilization data, satisfaction benchmarks, and evidence that their clinical model reduces cost across the full course of care.
Compliance readiness has become a genuine selection criterion, not a footnote. The Departments of Labor, Treasury, and Health and Human Services have proposed new pathways for offering fertility benefits as expected benefits, outside a major medical plan, according to Nixon Peabody. That regulatory movement is real and ongoing. Vendors who cannot speak fluently to ERISA, ACA, and expected benefit structures are not ready for what is coming, regardless of how strong their clinical offering looks on paper.
What Vendors Need to Prove to Win
The vendors closing deals right now are not winning on breadth of coverage. They are winning on specificity. Retention impact is the clearest lever available: 66% of employees say they have taken or would consider taking a new job for better reproductive and family health benefits, according to Maven. A vendor that can translate that statistic into a defensible cost-of-turnover model for a specific employer segment has a sales advantage that generic messaging cannot match.
Brokers remain the gatekeepers in most of these deals, and vendors who treat broker relationships as a partnership tend to move faster through the pipeline than those who treat them as a distribution channel. Brokers bring market benchmarks, vendor vetting experience, and negotiating leverage that employers rely on heavily. Positioning a broker as a co-advisor changes how quickly a deal moves.
Inclusive design is no longer a marketing checkbox. It shows up in actual sales conversations as a qualifying question, and vendors who cannot speak specifically to how their program serves nontraditional family-building paths are getting screened out earlier in the process than they realize.
Where This Leaves the Market
Fertility benefits illustrate something bigger happening across women’s health as a category: rapid legitimacy, fast-growing vendor density, and a growing distance between employers who know how to evaluate this space and vendors who know how to sell into it well. This is the first installment in a Brivio Health Insights series on growth in women’s health. Subscribe to follow along with the rest of the series.
